Expression And Clinical Significance Of DPT In Bladder Urothelial Carcinoma

Objective: To analyze the expression and clinic significance of Jun dermatopontin,DPT in bladder urothelial carcinoma.Methods: In the normal clinical work,the relevant information of patients with urothelial carcinoma of the bladder was mainly collected.Patients undergoing cystectomy were selected for intraoperative tissue collection.Tumor tissue and the corresponding paracancerous tissue were collected simultaneously from 1 patient.From December18,2018,solstice to August 14,2020,a total of 32 appropriate patient specimen tissues were collected in the urology department of our hospital.Then,the m RNA expression level of DPT was determined by reverse rate PCR,and the correlation analysis of clinical data was conducted.Results:1.The expression level of DPT in the collected tumor tissues and corresponding paracancerous tissues was measured,and the expression level of DPT in the tumor tissues was only 2.4% of that in the paracancerous tissues.(P < 0.05).2.The AUC of DPT in identifying bladder cancer was 0.869(95%CI: 0.784～0.955).The calculated cutoff value was 6.765,and the sensitivity and specificity were 81.3% and 78.1%respectively.3.In the collected samples,the expression of DPT in tumor tissue was related to the muscle invasion.The expression of DPT m RNA in NMIBC patients was relatively high,P=0.017.It’s statistically significant,of course(P < 0.05).Similarly,in clinical T staging,the expression level of DPT was also significantly different,and a statistical analysis of the difference showed that P=0.012,which was statistically significant.However,there was no correlation between DPT expression in bladder urothelial carcinoma and lymph node metastasis,pathological grade,age and gender(P >0.05).Conclusions: DPT is closely related to the invasion of bladder cancer,and its expression is low in tumor tissue,suggesting that DPT may play a role in the development and progression of bladder cancer as a tumor suppressor.